X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (185) 185
Publication (17) 17
Book / eBook (2) 2
Book Review (1) 1
Conference Proceeding (1) 1
Dissertation (1) 1
Magazine Article (1) 1
Newspaper Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (84) 84
oncology (71) 71
index medicus (68) 68
male (57) 57
female (56) 56
middle aged (51) 51
aged (46) 46
cancer (40) 40
adult (39) 39
chemotherapy (33) 33
care and treatment (24) 24
survival (22) 22
radiotherapy (21) 21
prognosis (20) 20
treatment outcome (20) 20
antineoplastic combined chemotherapy protocols - therapeutic use (19) 19
metastasis (19) 19
analysis (18) 18
patients (18) 18
therapy (18) 18
retrospective studies (16) 16
surgery (16) 16
antineoplastic agents - therapeutic use (15) 15
head and neck neoplasms - pathology (15) 15
hematology, oncology and palliative medicine (15) 15
head (14) 14
neoplasm staging (14) 14
squamous cell carcinoma (14) 14
squamous-cell carcinoma (14) 14
aged, 80 and over (13) 13
hematology (13) 13
research (13) 13
urology & nephrology (13) 13
cisplatin (12) 12
head and neck neoplasms - drug therapy (12) 12
patient outcomes (12) 12
radiation-therapy (12) 12
survival rate (12) 12
tumors (12) 12
cancer therapies (11) 11
carcinoma, squamous cell - drug therapy (11) 11
disease-free survival (11) 11
metastases (11) 11
carcinoma (10) 10
clinical trials (10) 10
combined modality therapy (10) 10
drug therapy (10) 10
follow-up studies (10) 10
head and neck cancer (10) 10
lung cancer (10) 10
medicine & public health (10) 10
neck (10) 10
neoplasms (10) 10
otorhinolaryngology (10) 10
radiology, nuclear medicine & medical imaging (10) 10
antineoplastic combined chemotherapy protocols - adverse effects (9) 9
carcinoma, squamous cell - pathology (9) 9
dosage and administration (9) 9
kaplan-meier estimate (9) 9
lung neoplasms - drug therapy (9) 9
management (9) 9
mutation (9) 9
neck-cancer (9) 9
survival analysis (9) 9
trial (9) 9
carcinoma, non-small-cell lung - drug therapy (8) 8
carcinoma, squamous cell - mortality (8) 8
health aspects (8) 8
medicine (8) 8
mortality (8) 8
radiology (8) 8
radiology and nuclear medicine (8) 8
radiotherapy dosage (8) 8
antineoplastic agents - adverse effects (7) 7
carcinoma, squamous cell - radiotherapy (7) 7
disease progression (7) 7
erlotinib (7) 7
quality of life (7) 7
squamous cell carcinoma of head and neck (7) 7
toxicity (7) 7
tyrosine kinase inhibitor (7) 7
antineoplastic agents - administration & dosage (6) 6
biomarkers (6) 6
cancer research (6) 6
carboplatin - administration & dosage (6) 6
carcinoma, non-small-cell lung - pathology (6) 6
cisplatin - administration & dosage (6) 6
epidemiology (6) 6
expression (6) 6
gefitinib (6) 6
head and neck neoplasms - mortality (6) 6
head and neck neoplasms - therapy (6) 6
lung neoplasms - pathology (6) 6
lymph nodes (6) 6
oncology, experimental (6) 6
open-label (6) 6
population (6) 6
prostate cancer (6) 6
risk factors (6) 6
seer program (6) 6
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


American Journal of Cancer, ISSN 1175-6357, 2005, Volume 4, Issue 4, pp. 253 - 254
Journal Article
by Cohen, Ezra E W and Cohen, Ezra and Soulières, Denis and Le Tourneau, Christophe and Dinis, Jose and Dinis, José and Licitra, Lisa and Ahn, Myung-Ju and Soria, Ainara and Machiels, Jean-Pascal and Mach, Nicolas and Mehra, Ranee and Burtness, Barbara Ann and Burtness, Barbara and Zhang, Pingye and Cheng, Jonathan and Swaby, Ramona F and Harrington, Kevin and Harrington, Kevin J and Acosta-Rivera, Mirelis and Adkins, Douglas R and Aghmesheh, Morteza and Airoldi, Mario and Aleknavicius, Eduardas and Al-Farhat, Yousuf and Algazi, Alain P and Almokadem, Salah and Alyasova, Anna and Bauman, Jessica R and Benasso, Marco and Berrocal, Alfonso and Bray, Victoria and Caponigro, Francesco and Castro, Ana and Cescon, Terrence P and Chan, Kelvin and Chaudhry, Arvind and Chauffert, Bruno and Csoszi, Tibor and De Boer, J.P and Delord, Jean-Pierre and Dietz, Andreas and Dupuis, Charlotte and Digue, Laurence and Erfan, Jozsef and Escobar Alvarez, Yolanda and Evans, Mererid and Fidler, Mary Jo and Forster, Martin David and Friesland, Signe and Ganti, Apar K and Geoffrois, Lionnel and Grant, Cliona and Gruenwald, Viktor and Hoffmann, Thomas and Horvai, Geza and Inciura, Arturas and Jang, Raymond and Jankowska, Petra and Jimeno, Antonio and Joseph, Mano and Juarez Ramiro, Alejandro and Karaszewska, Boguslawa and Kawecki, Andrzej and Keilholz, Ulrich and Keller, Ulrich and Kim, Sung-Bae and Kocsis, Judit and Kotecki, Nuria and Kozloff, Mark F and Lambea, Julio and Landherr, Laszlo and Lantsukhay, Yuri and Lazarev, Sergey Alexandrovich and Lee, Lip Way and Lifirenko, Igor Dmitrievich and Martincic, Danko and Matorin, Oleg Vladmirovhich and McGrath, Margaret and Misiukiewicz, Krzysztof and Morris, John C and Mufazalov, Fagim Fanisovich and Niu, Jiaxin and Pamoorthy Srinivasan, Devraj and Perez Segura, Pedro and Rauch, Daniel and Ribeiro, Maria Leonor and Rodriguez, Cristina and Rolland, Frederic and Russo, Antonio and Ruzsa, Agnes and Sanches, Frederico and Shin, Sang-Won and Shtiveland, Mikhail and Soulieres, Denis and Specenier, Pol and Szekanecz, Eva and Szota, Judit and van Herpen, Carla M.L and Velez-Cortes, Hector A and ... and Keynote-040 Investigators and KEYNOTE-040 investigators
The Lancet, ISSN 0140-6736, 01/2019, Volume 393, Issue 10167, pp. 156 - 167
There are few effective treatment options for patients with recurrent or metastatic head-and-neck squamous cell carcinoma. Pembrolizumab showed antitumour... 
CRITERIA | TRIAL | MEDICINE, GENERAL & INTERNAL | NIVOLUMAB | CANCER | CHEMOTHERAPY | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Docetaxel - adverse effects | Humans | Middle Aged | Squamous Cell Carcinoma of Head and Neck - pathology | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Neoplasm Recurrence, Local - drug therapy | Male | Cetuximab - therapeutic use | Cetuximab - adverse effects | Docetaxel - administration & dosage | Antibodies, Monoclonal, Humanized - administration & dosage | Squamous Cell Carcinoma of Head and Neck - drug therapy | Female | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Drug Administration Schedule | Head and Neck Neoplasms - drug therapy | Kaplan-Meier Estimate | Disease Progression | Head and Neck Neoplasms - pathology | Methotrexate - adverse effects | Squamous Cell Carcinoma of Head and Neck - secondary | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Cetuximab - administration & dosage | Methotrexate - administration & dosage | Aged | Methotrexate | Squamous cell carcinoma | Metastasis | Therapy | Toxicity | Perforation | Clinical trials | Oncology | Cancer therapies | Metastases | Skin cancer | Anticancer properties | Pembrolizumab | Randomization | Motivation | Platinum | Neck | Safety | Medical treatment | Fatigue | Hypothyroidism | Survival | Patients | Chemotherapy | Interactive systems | Large intestine | Head and neck cancer | Ligands | Tumors
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 3, pp. 323 - 335
Journal Article
Journal of Cellular and Molecular Medicine, ISSN 1582-1838, 08/2014, Volume 18, Issue 8, pp. 1519 - 1539
Patients with non‐small‐cell lung cancer (NSCLC) appear to gain particular benefit from treatment with epidermal growth factor receptor (EGFR) tyrosine‐kinase... 
mutation | afatinib | epidermal growth factor receptor (EGFR) | erlotinib | non‐small‐cell lung cancer (NSCLC) | tyrosine‐kinase inhibitor | gefitinib | first line | icotinib | Tyrosine-kinase inhibitor | Icotinib | Afatinib | Erlotinib | First line | Non-small-cell lung cancer (NSCLC) | Epidermal growth factor receptor (EGFR) | Mutation | Gefitinib | GENE-MUTATIONS | MEDICINE, RESEARCH & EXPERIMENTAL | 1ST-LINE TREATMENT | GROWTH-FACTOR-RECEPTOR | PROGRESSION-FREE SURVIVAL | FRONT-LINE CHEMOTHERAPY | non-small-cell lung cancer (NSCLC) | tyrosine-kinase inhibitor | CELL BIOLOGY | CELL LUNG-CANCER | TYROSINE KINASE INHIBITORS | CHEMOTHERAPY-NAIVE PATIENTS | PHASE-II TRIAL | MOLECULAR PREDICTORS | Lung Neoplasms - genetics | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Meta-Analysis as Topic | Prognosis | Carcinoma, Non-Small-Cell Lung - genetics | Lung Neoplasms - mortality | Humans | Survival Rate | Mutation - genetics | Carcinoma, Non-Small-Cell Lung - mortality | Protein Kinase Inhibitors - therapeutic use | Review Literature as Topic | Carcinoma, Non-Small-Cell Lung - drug therapy | Care and treatment | Chemotherapy | Genetic aspects | Lung cancer, Non-small cell | Patient outcomes | Cancer | Epidermal growth factor | Kinases | Cancer therapies | Lung cancer | Tyrosine | Permutations | Epidermal growth factor receptors | Medical services | Non-small cell lung carcinoma | Oncology | Disease control | Patients | Datasets | Studies | Biopsy | Writing | Growth factors | Tumors | Original
Journal Article
Journal of Cellular and Molecular Medicine, ISSN 1582-1838, 01/2010, Volume 14, Issue 1‐2, pp. 51 - 69
•  Introduction •  Literature review ‐  Molecular biology of EGFR mutations ‐  Clinical characteristics of NSCLC patients with EGFR mutations ‐  Genetic... 
lung cancer | mutation | epidermal growth factor receptor | erlotinib | adenocarcinoma | gefitinib | tyrosine kinase inhibitor | chemotherapy | Adenocarcinoma | Chemotherapy | Erlotinib | Tyrosine kinase inhibitor | Lung cancer | Mutation | Gefitinib | Epidermal growth factor receptor | MEDICINE, RESEARCH & EXPERIMENTAL | GROWTH-FACTOR-RECEPTOR | IN-SITU-HYBRIDIZATION | TREATED JAPANESE PATIENTS | GEFITINIB SENSITIVITY | CELL BIOLOGY | CHEMOTHERAPY-NAIVE PATIENTS | CLINICOPATHOLOGICAL CHARACTERISTICS | PHASE-II TRIAL | BRONCHIOLOALVEOLAR-CARCINOMA | GENE COPY NUMBER | Lung Neoplasms - genetics | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Prospective Studies | Carcinoma, Non-Small-Cell Lung - genetics | Humans | Treatment Outcome | Clinical Trials as Topic | Disease-Free Survival | Protein Kinase Inhibitors - therapeutic use | Review Literature as Topic | Sensitivity and Specificity | Publication Bias | Retrospective Studies | Carcinoma, Non-Small-Cell Lung - drug therapy | Tyrosine | Permutations | Sensitivity analysis | Statistical analysis | Epidermal growth factor receptors | Clinical trials | Non-small cell lung carcinoma | Kinases | Cancer therapies | Patients | Subgroups | Literature reviews | Studies | Epidermal growth factor | Data search | Ligands | Median (statistics) | Molecular biology | Growth factors | Tumors | Reviews
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 03/2019, Volume 380, Issue 12, pp. 1116 - 1127
Journal Article